“天然合剂”血脂康对绝经早期高胆固醇血症女性胆固醇代谢标志物影响的研究

冯妍; 卢淑立; 靳相公; 高杰; 王以新; 徐浩; 王绿娅

doi:10.1007/s11655-021-3499-y

Your Location：

Home >

Browse articles >

“天然合剂”血脂康对绝经早期高胆固醇血症女性胆固醇代谢标志物影响的研究

Original Article | Updated：2022-03-18

- “天然合剂”血脂康对绝经早期高胆固醇血症女性胆固醇代谢标志物影响的研究
- Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia
- Chinese Journal of Integrative Medicine 2022年28卷第3期页码：202-207
- Affiliations：
  
  1.Department of General Medicine, Beijing Anzhen Hospital,Capital Medical University, Beijing(100029), China
  2.Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
- Author bio：
  
  Prof. WANG Yi-xin, E-mail:wangyixin6417@sina.com
- Funds：
  
  National Natural Science Foundation of China(81703932);Beijing Natural Science Foundation(7144205);The Youth Talent Fund of Beijing Municipal Bureau of Health Administration Grants(QML20190605);Beijing Science and Technology Development Fund Project of Traditional Chinese Medicine(JJ-2020-01);Science and Technology Plan of Chaoyang District, Beijing(CYSF2027)
- DOI：10.1007/s11655-021-3499-y
  中图分类号：
- 纸质出版日期：2022-03-01，
  
  网络出版日期：2021-08-25，
  
  录用日期：2021-01-02
Scan for full text
冯妍, 卢淑立, 靳相公, 等. “天然合剂”血脂康对绝经早期高胆固醇血症女性胆固醇代谢标志物影响的研究[J]. Chinese Journal of Integrative Medicine, 2022,28(3):202-207.

Yan FENG, Shu-li LU, Xiang-gong JIN, et al. Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia[J]. Chinese Journal of Integrative Medicine, 2022,28(3):202-207.
冯妍, 卢淑立, 靳相公, 等. “天然合剂”血脂康对绝经早期高胆固醇血症女性胆固醇代谢标志物影响的研究[J]. Chinese Journal of Integrative Medicine, 2022,28(3):202-207. DOI： 10.1007/s11655-021-3499-y.

Yan FENG, Shu-li LU, Xiang-gong JIN, et al. Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia[J]. Chinese Journal of Integrative Medicine, 2022,28(3):202-207. DOI： 10.1007/s11655-021-3499-y.

摘要

目的:

本研究旨在分析血脂康对绝经早期高胆固醇血症妇女胆固醇合成和吸收的血脂水平标志物的影响

并初步探讨其降脂机制.

方法:

本研究将首都医科大学北京安贞医院收治的90例绝经早期高胆固醇血症妇女随机分配接受血脂康 (每日1200毫克

口服) 或阿托伐他汀 (每日10毫克

口服) 治疗. 在干预前和干预后8周

检测相关生化指标、胆固醇合成标志物 (角鲨烯、二氢胆固醇、脱氢胆固醇和板条甾醇) 和吸收标志物 (营甾醇、豆甾醇和谷甾醇) 的水平.

结果:

治疗8周后

血脂康较基线明显降低TC水平 (5.45±0.86 vs 4.93±0.83

P=0.000) 、甘油三酯 (1.66±1.34 vs 1.31±0.68

P=0.003) 、LDL胆固醇 (3.34±0.76 vs 2.93±0.70

P=0.001)

同时阿托伐他汀也较基线明显降低总胆固醇 (5.69±0.86 vs 4.98±1.14

P=0.001) 、甘油三酯 (1.91±1.07 vs 1.41±0.60

P=0.001) 、LDL胆固醇 (3.42±0.79 vs 2.99±0.90

P = 0.001) . 血脂康较基线明显降低角鲨烯 (0.83±0.41

vs 0.53±0.27

P=0.001) 、脱氢胆固醇 (5.60±3.24 vs 3.80±1.63

P=0.001) 、7-烯胆甾烷醇 (7.44±7.53 vs 4.08±2.66

P=0.000) 水平

而阿托伐他汀仅较基线明显降低角鲨烯 (0.91±0.87 vs . 0.59±0.29

P=0.001) 水平. 所有胆固醇吸收标志物治疗前后差异无统计学意义 (P > 0.05)

但下降趋势更为明显.

结论:

血脂康可能通过其“天然合剂”中的麦角甾醇和类黄酮类物质对绝经早期女性高胆固醇血症患者的胆固醇的合成代谢产生更全面的影响.

Abstract

Objective:

To analyze the effect of Xuezhikang on the markers of the serum lipid levels of cholesterol synthesis and absorption in early menopausal women with hypercholesterolemia

and preliminarily explore its lipid-lowering mechanism.

Methods:

A total of 90 early menopausal women with hypercholesterolemia were enrolled from December

2014 to May

2016 from Beijing Anzhen Hospital

Capital Medical University

who were randomly allocated to receive Xuezhikang (1200 mg/d

orally) or atorvastatin (10 mg/d

orally) according to a random number table. Serum levels of some related biomarkers

including cholesterol synthesis markers (squalene

dihydrocholesterol

dehydrocholesterol

and lathosterol)

and absorption markers (campesterol

stigmasterol

and sitosterol) as well as safety indices were obtained at baseline and after 8 weeks of the intervention.

Results:

Eight weeks after treatment

both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol

triglycerides

low density cholesterol compared to baseline (all

0.01). Xuezhikang significantly reduced the levels of squalene

dehydrocholesterol and lathosterol compared to baseline (all

0.01)

but atorvastatin only significantly reduced the level of squalene (

0.01)

compared to baseline. All cholesterol absorption markers showed no significant differences before and after treatment (

0.05)

however

a more obvious downward trend was shown in the Xuezhikang group. In addition

all the safety indices showed no significant differences between the two groups. Although the creatinekinase level in the Xuezhikang group was significantly higher

it remained within the safe range.

Conclusions:

Xuezhikang may have more comprehensive effects on the markers of cholesterol synthesis and metabolism in early menopausal women with hypercholesterolemia through ergosterol and flavonoids in its "natural polypill."

关键词

Keywords

early menopausal womenhypercholesterolemiaXuezhikangcholesterol metabolism markersatorvastatin

references

Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.

Feng Y, Xu H, Chen K. Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. J Altern Complement Med 2012;4:318-328.

Mignarri A, Magni A, Del Puppo M, Gallus GN, Björkhem I, Federico A, et al. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis 2016;39:75-83.

Chen PP, Jiang L, Wang W, Wen WH, Kuang ZM, Wang LY. Effect of Xuezhikang on serum cholesterol metabolism markers in patients with hypercholesterolemia. Chin Med(Chin) 2017;1:28-32.

Xu HY, Xiang ZM, Lu ZL. Summary and interpretation of guidelines for prevention and treatment of dyslipidemia in Chinese adults (2007). Chin J Geriatr Heart Brain Vessel Dis (Chin) 2008;3:238-239.

Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1996;866:1-107.

Li YH, Jia ZR, Jiang L, Yang Q, Wang LY. Meta-analysis on lipid-regulation effect of Xuezhikang in patients with coronary heart disease complicating hyperlipemia. Chin J Evid-Base Cardiovasc Med (Chin) 2014;1:25-30.

Cheng YC. Clinical observation on effect of combination ezetimibe with Xuezhikang on eholestin extract. J Qiqibar Univ Med (Chin) 2014;16:2397-2399.

Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyshpidemia. PLOS One 2014;6:e98611.

Xie J, Li D, Wang M. Detection of lovastatin in Xuezgikang capsule by HPLC method. China Pharm (Chin)2010;45:4287-4288.

Feng Y, Wang YX, Zhang PX, Zhang MM, Kang CY. Effect of Xuezhikang on lipid metabolism in perimenopausal women with hyperlipemia. Chin Med 2018;10:1441-1444.

Wu Z, Wu D, Jiang J, Chen A, Zheng DD, Li J, et al.Efficacy and safety of Xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label,non-inferiority study. BMJ Open 2020;5:e034585.

Momtazi-Borojeni AA, Katsiki N, Pirro M, Banach M,Rasadi KA, Sahebkar A. Dietary natural products as emerging lipoprotein(a)-lowering agents. J Cell Physiol 2019;8:12581-12594.

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle 2021. doi:10.1002/jcsm.12654http://doi.org/10.1002/jcsm.12654. Online ahead of print.

Malina DM, Fonseca FA, Barbosa SA, Kasmas SH,Machado VA, França CN, et al. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens. J Clin Lipidol 2015;4:542-552.

Lu WN, Zheng FP, Lai DW, Li H. Xuezhikang reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family. Chin J Integr Med 2016;8:611-618.

Jia Y, Zhang Y, Liu J, Guo YL, Xu RX, Li JJ. Short- and long-term effects of Xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.Chin J Integr Med 2016;2:96-100.

Gao Y, Chen X, Li C, Wang H, Tian J, Fu F. Toxicological evaluation of red rice yeast extract, Xuezhikang: acute,26-week chronic and genotoxicity studies. Regul Toxicol Pharmacol 2020;114:104654.

Jia W, Li Y, Wan J, Cui X, Lu J, Liu J, et al. Effects of Xuezhitong in patients with hypertriglyceridemia: a multicentre, randomized, double-blind, double simulation,positive drug and placebo parallel control study. Cardiovasc Drugs Ther 2020;4:525-534.

Klingelhöfer I, Morlock GE. Lovastatin in lactone and hydroxy acid forms and citrinin in red yeast rice powders analyzed by HPTLC-UV/FLD. Anal Bioanal Chem 2019;25:6655-6665.

Zheng J, Xiao T, Ye P, Miao D, Wu H. Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study. Braz J Med Biol Res 2017;10:e6363.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据